Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel maintenance in early stage ovarian cancer
NCT00003644Phase 3Completed
- Sponsor
- GOG Foundation
- Start
- Oct 1998
- Primary completion
- Mar 2010
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of paclitaxel in ovarian cancer (2 arms), sponsored by GOG Foundation. Primary endpoints: Progression-free Survival at 5 years, Overall Survival at 96 months and 1 more. Started Oct 1998; status: completed.
02
Drugs
paclitaxel
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT00003644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003644.